Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Springworks Therapeutics Inc (SWTX)

Springworks Therapeutics Inc (SWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,832,227
  • Shares Outstanding, K 74,936
  • Annual Sales, $ 191,590 K
  • Annual Income, $ -258,130 K
  • EBIT $ -278 M
  • EBITDA $ -275 M
  • 60-Month Beta 0.76
  • Price/Sales 19.47
  • Price/Cash Flow N/A
  • Price/Book 7.70

Options Overview Details

View History
  • Implied Volatility 155.38% ( +5.49%)
  • Historical Volatility 105.25%
  • IV Percentile 98%
  • IV Rank 88.69%
  • IV High 169.36% on 01/10/25
  • IV Low 45.76% on 09/03/24
  • Put/Call Vol Ratio 0.34
  • Today's Volume 13,250
  • Volume Avg (30-Day) 18,069
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 168,936
  • Open Int (30-Day) 105,919

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.79
  • Number of Estimates 6
  • High Estimate -0.65
  • Low Estimate -0.93
  • Prior Year -1.18
  • Growth Rate Est. (year over year) +33.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.63 +9.67%
on 03/10/25
62.00 -17.52%
on 02/20/25
-6.29 (-10.95%)
since 02/14/25
3-Month
31.95 +60.04%
on 01/15/25
62.00 -17.52%
on 02/20/25
+12.84 (+33.52%)
since 12/13/24
52-Week
28.21 +81.28%
on 10/24/24
62.00 -17.52%
on 02/20/25
+1.66 (+3.35%)
since 03/14/24

Most Recent Stories

More News
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week

Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.

TNYA : 0.6989 (+4.28%)
CSCI : 3.29 (+5.79%)
MLYS : 14.25 (+5.56%)
SWTX : 51.14 (+2.75%)
MGX : 1.9400 (+1.57%)
SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?

Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.

VTI : 276.99 (+2.14%)
XBI : 87.13 (+1.35%)
IWM : 202.89 (+2.42%)
SWTX : 51.14 (+2.75%)
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

SWTX : 51.14 (+2.75%)
SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect

Recent investor enthusiasm has been fueled by reports that German healthcare giant Merck KGaA is in advanced talks to acquire SpringWorks.

VTI : 276.99 (+2.14%)
XBI : 87.13 (+1.35%)
IWM : 202.89 (+2.42%)
SWTX : 51.14 (+2.75%)
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN 

SWTX : 51.14 (+2.75%)
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN 

SWTX : 51.14 (+2.75%)
Springworks Stock Soars To Nearly 3-Year High On Buyout Buzz, Retail Sentiment Rockets

Reuters reported that German healthcare and technology group Merck KGaA is in advanced talks to acquire the company.

VTI : 276.99 (+2.14%)
XBI : 87.13 (+1.35%)
IWM : 202.89 (+2.42%)
SWTX : 51.14 (+2.75%)
SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025

SWTX : 51.14 (+2.75%)
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down

SpringWorks Therapeutics SWTX announced preliminary net product revenues for fourth-quarter and full-year 2024 for its sole marketed drug, Ogsiveo (nirogacestat). The drug is approved for treating adult...

CTMX : 0.6496 (+9.95%)
VYGR : 3.90 (-4.06%)
CSTL : 19.29 (+2.83%)
SWTX : 51.14 (+2.75%)
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference

SWTX : 51.14 (+2.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics...

See More

Key Turning Points

3rd Resistance Point 54.69
2nd Resistance Point 53.10
1st Resistance Point 52.12
Last Price 51.14
1st Support Level 49.55
2nd Support Level 47.96
3rd Support Level 46.98

See More

52-Week High 62.00
Last Price 51.14
Fibonacci 61.8% 49.09
Fibonacci 50% 45.10
Fibonacci 38.2% 41.12
52-Week Low 28.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar